New formulations and approaches in the medical treatment of acromegaly

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 4, 2010, Pages 350-355

  Debono, Miguel ^a   Newell Price, John ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

acromegaly; BIM 23A760; chimeric somatostatin dopamine molecules; pasireotide (SOM 230); pegvisomant

Indexed keywords

ANGIOPEPTIN; BIM 23197; BIM 23A760; BIM 23A779; BIM 53097; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; UNCLASSIFIED DRUG; HORMONE ANTAGONIST; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; HORMONE RELEASE; HUMAN; REVIEW; ADENOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMPLICATION; DOSE RESPONSE; EVALUATION STUDY; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; MEDICINAL CHEMISTRY; METABOLISM; SECRETION (PROCESS); SYNTHESIS; TRENDS;

ACROMEGALY; ADENOMA; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; SOMATOSTATIN;

EID: 77955768701     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833ab099     Document Type: Review

References (55)

1. Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355:2558-2573.
2. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008; 93:61-67.
3. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol/Eur Fed Endocrine Soc 2008; 159:89-95.
4. Reichlin S. Somatostatin. N Engl J Med 1983; 309:1495-1501.
5. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001; 12 (Suppl 2):S31-S36.
6. Miller GM, Alexander JM, Bikkal HA, et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80:1386-1392.
7. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metab Clin Exp 1996; 45 (8 Suppl 1):27-30.
8. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metab Clin Exp 2005; 54:1276-1281.
9. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87:3013-3018.
10. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86:2779-2786.
11. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 2002; 56:65-71.
12. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112-2118.
13. Colao A, Auriemma RS, GaldieroM, et al. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009; 94:3746-3756.
14. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:1856-1863.
15. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002; 87:4554-4563.
16. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol 2009; 70:757-768.
17. Clayton RN. How many surgeons to operate on acromegalic patients? Clin Endocrinol 1999; 50:557-559.
18. Ambrilia Reports. Positive final phase III results for its octreotide formulation C2L. Market Wire FindArticlescom; 21 March 2010. http://findarticles.com/ p/articles/mi-pwwi/is-200805/ai-n25416706/pg-2/.
19. Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol 2004; 61:224-231.
20. Indevus Pharmaceuticals Reports. Positive results of phase II octreotide implant trial. drugscom. 21 Mar, 2010. http://www.drugs.com/clinical- trials/indevus-pharmaceuticals-reports-positive-results-phase-ii- octreotideimplant- trial-2804.html.
21. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol/Eur Fed Endocrine Soc 2009; 161:331-338.
22. Thorner MO, Chait A, Aitken M, et al. Bromocriptine treatment of acromegaly. BMJ 1975; 1:299-303.
23. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
24. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol 2004; 61:209-215.
25. Kovacs K, Horvath E. Pathology of pituitary tumors. Endocrinol Metab Clin N Am 1987; 16:529-551.
26. Moyes VJ, Metcalfe KA, Drake WM. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur J Endocrinol/Eur Federat Endocrine Soc 2008; 159:541-545.
27. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83:374-378.
28. Colao A, Filippella M, Pivonello R, et al. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol/Eur Federat Endocrine Soc 2007; 156 (Suppl 1):S57-63.
29. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol/Eur Federat Endocrine Soc 2005; 152:569-574.
30. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinsons disease. N Engl J Med 2007; 356:39-46.
31. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29-38.
32. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Rev 2002; 23:623-646.
33. Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: past and present. Eur J Endocrinol/Eur Federat Endocrine Soc 2009; 161 (Suppl 1): S3-S10.
34. Buhk JH, Jung S, Psychogios MN, et al. Tumor volume of growth hormonesecreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 2010; 95:552-558.
35. Ghigo E, Biller BM, Colao A, et al. Comparison of pegvisomant and longacting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Investig 2009; 32:924-933.
36. Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol/Eur Federat Endocrine Soc 2009; 161:21-25.
37. Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: longterm safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol/Eur Federat Endocrine Soc 2009; 160:529-533.
38. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005; 90:5627-5631.
39. Trainer PJ, Ezzat S, DSouza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 2009; 71:549-557.
40. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68:844-850.
41. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004; 80 (Suppl 1):47-50.
42. Lesche S, Lehmann D, Nagel F, et al. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 2009; 94:654-661.
43. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Molec Cell Endocrinol 2008; 286:69-74.
44. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulinlike growth factor-I axis in rats, primates, and dogs. Endocrinology 2002; 143:4123-4130.
45. Poll F, Lehmann D, Illing S, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Molec Endocrinol 2010; 24:436-446.
46. Saveanu A, Gunz G, Dufour H, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86:140-145.
47. Ren SG, Taylor J, Dong J, et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88:4239-4245.
48. van der Hoek J, de HerderWW,FeeldersRA, et al.A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004; 89:638-645.
49. Farrall AJ GJ, Ruffin M, Petersenn S. Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a phase II extension study. Endocr Abstr 2008; 16:OC14.
50. Petersenn S BJ, Bollerslev J, Arafat AM, et al. Pasireotide LAR shows efficacy in patients with acromegaly: interim results from a randomised, multicentre, phartmacokinetic/pharmacodynamic, phase I study [abstract #OR41-5.]. Presented at 90th Annual Meeting of the American Endocrine Society; 15-18 June 2008; San Fransisco, CA, USA; 2008.
51. Saveanu A, Lavaque E, Gunz G, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87:5545-5552.
52. Ren SG, Kim S, Taylor J, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88:5414-5421.
53. Jaquet P, Gunz G, Saveanu A, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol/Eur Federat Endocrine Soc 2005; 153:135-141.
54. Jaquet P, Gunz G, Saveanu A, et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Investig 2005; 28:21-27.
55. Saveanu A, Gunz G, Guillen S, et al. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006; 83:258-263.